Fatal pulmonary haemorrhage with the combined use of abciximab and fibrinolytic agent.
The increased bleeding risk associated with the use of abciximab has been well reported. The risk appears to be amplified when abciximab is administered concurrently with a fibrinolytic agent. We report and review the literature on the occurrence of a case of fatal pulmonary haemorrhage, a rare bleeding complication, in a patient who received both these drugs.
Tan
H C
HC
Cardiac Department, National University Hospital, 5 Lower Kent, Ridge Road, Singapore 119074. tanhc@nuh.com.sg
Low
A
A
Ng
K S
KS
Budiono
B
B
Sutandar
A
A
Chia
B L
BL
Lim
Y T
YT
D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D017809:Fatal Outcome; D005343:Fibrinolytic Agents / Q000009:adverse effects*; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects*; D008171:Lung Diseases / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D013300:Streptokinase / Q000009:adverse effects*
D000911:Antibodies, Monoclonal; D005343:Fibrinolytic Agents; D007140:Immunoglobulin Fab Fragments; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D013300:Streptokinase; D000077284:Abciximab